Chart-Typ:
Zeitraum:
| Riot Platforms, Inc.: Riot Announces December 2025 Production and Operations Updates | CASTLE ROCK, Colo., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Riot Platforms, Inc. (NASDAQ: RIOT) ("Riot" or "the Company"), a Bitcoin-driven industry leader in the development of large-scale data centers... ► Artikel lesen |
| Riot Platforms, Inc.: Riot Platforms Announces Chief Financial Officer Transition | CASTLE ROCK, Colo., Jan. 02, 2026 (GLOBE NEWSWIRE) -- Riot Platforms, Inc. (NASDAQ: RIOT) ("Riot" or the "Company") today announced the appointment of Jason Chung as Chief Financial Officer of the... ► Artikel lesen |
| Riot Platforms, Inc.: Riot Announces November 2025 Production and Operations Updates | CASTLE ROCK, Colo., Dec. 04, 2025 (GLOBE NEWSWIRE) -- Riot Platforms, Inc. (NASDAQ: RIOT) ("Riot" or "the Company"), a Bitcoin-driven industry leader in the development of large-scale data centers... ► Artikel lesen |
| Electra Battery Materials Corporation Provides Update on Refinery Project Progress | TORONTO, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Electra Battery Materials Corporation (NASDAQ: ELBM; TSX-V: ELBM) ("Electra" or the "Company"), a leader in advancing North America's critical minerals processing... ► Artikel lesen |
| Electra Battery Materials Corporation Signs Agreement with North American pCAM Company | TORONTO, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Electra Battery Materials Corporation (NASDAQ: ELBM; TSX-V: ELBM) ("Electra" or the "Company"), a leader in advancing North America's critical minerals processing... ► Artikel lesen |
| Electra Battery Materials Corporation Files Third Quarter 2025 Financial Reports | TORONTO, Nov. 13, 2025 (GLOBE NEWSWIRE) -- Electra Battery Materials Corporation (NASDAQ: ELBM; TSX-V: ELBM) ("Electra" or the "Company") announces the filing of its financial results for the third... ► Artikel lesen |
| BioCryst Pharmaceuticals, Inc.: BioCryst Announces Preliminary Full Year 2025 ORLADEYO (berotralstat) Net Revenue of $601 Million (+37 percent y-o-y), Beating Prior Guidance Range | -Excluding European ORLADEYO revenue for the full year 2025, preliminary 2025 ORLADEYO net revenue was $563 million (+43 percent y-o-y on a comparable basis)- -ORLADEYO net revenue expected to be... ► Artikel lesen |
| XFRA BO1: WIEDERAUFNAHME/RESUMPTION | FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:INSTRUMENT NAME... ► Artikel lesen |
| BioCryst Pharmaceuticals, Inc.: BioCryst Announces FDA Approval of ORLADEYO (berotralstat) Oral Pellets, First and Only Oral Prophylactic Treatment for Patients with HAE Aged 2 to <12 Years | - ORLADEYO now first and only targeted oral prophylactic therapy for patients with HAE aged 2 and older- -Oral pellet formulation provides child-friendly method of administration- -Showed early and... ► Artikel lesen |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu AARDVARK THERAPEUTICS INC finden Sie auf Wallstreet Online.